II. Indications
-
Severe Persistent Asthma
- Adjunct only
- Other Leukotriene Modifiers are preferred
III. Dosing
- Approved only in age >=12 years and only as adjunct in Severe Asthma
- Dose: 1200 mg orally two times daily
IV. Mechanism
- Attenuates bronchoconstriction and inflammation
-
Leukotriene Synthesis Inhibitor (inhibits 5-lipoxygenase)
- Contrast with Leukotriene Receptor Antagonists (Zafirlukast or Accolate, Montelukast or Singulair)
V. Adverse Effects
- See Leukotriene Receptor Antagonist
- More adverse effects than other Leukotriene Modifiers (e.g. Montelukast, Zafirlukast)
- Dyspepsia
- Nausea
- Hepatotoxicity (5% of patients)
- Monitor liver enzymes every 3 months
VI. Efficacy
- See See Leukotriene Receptor Antagonist
VII. Safety
- Pregnancy Category C
- Unknown safety in Lactation
VIII. Drug Interactions
- Zileuton increases other drug levels, potentiating their action
IX. Resources
X. References
- (2020) Drugs for Asthma, Med Lett Drug Ther 62: 193-200
- (1996) Med Lett Drugs Ther 38:111-2 [PubMed]
- (2000) Med Lett Drugs Ther 42:22-3 [PubMed]
- Scow (2007) Am Fam Physician 75:65-70 [PubMed]
- Wilson (2001) Chest 119:2021-6 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
zileuton (on 6/7/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ZILEUTON ER 600 MG TABLET | Generic | $10.02 each |
Ontology: zileuton (C0081408)
Definition (NCI_NCI-GLOSS) | A substance that is used to prevent asthma symptoms and that is being studied in the prevention of lung cancer. It belongs to the family of drugs called leukotriene blockers. |
Definition (NCI) | A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04) |
Definition (PDQ) | A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26667" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C063449 |
SnomedCT | 386180009, 108617005 |
English | N-(1-benzo(b)thien-2-ylethyl)-N-hydroxyurea, zileuton, (+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea, N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea, zileuton (Zyflo), zileuton (medication), ZILEUTON, zileuton [Chemical/Ingredient], Zileuton (product), Zileuton (substance), Zileuton, ZLT |
Spanish | zileutona, zileutón, zileutón (producto), zileutona (sustancia), zileutona (producto), zileutón (sustancia) |
Ontology: Zyflo (C0724508)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C063449 |
English | Zyflo, zyflo, Abbott brand of zileuton |